Mostly in high-income countries, diagnosis can combine clinical examination, including neuropsychological testing, brain imaging (e.g., 18F-fluorodeoxyglucose positron emission tomography (PET), magnetic resonance imaging, and amyloid or tau PET) [4,5], and cerebrospinal fluid (CSF) biomarkers in the case of Alzheimer’s disease (AD) [6]. This evidence concerns the gene MAPT and Alzheimer disease.